Capricor Therapeutics, Inc. · NASDAQ:CAPR
Capricor Therapeutics — Q1 2020 Earnings Presentation
6 slides from Capricor Therapeutics's earnings presentation, May 15, 2020
Slide 1: Q1 Earnings Call and Corporate Update
Capricor Q1 Earnings Call and Corporate Update 1 May 14, 2020 Earnings Call NASDAQ: CAPR
Slide 2: Forward-Looking Statements
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside Forward - Looking Statements 2 Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates ; the initiation, conduct, size, timing and results of discov
Slide 3: Immunomodulatory Effects of CAP-1002
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside Immunomodulatory Effects of CAP - 1002 CDCs: Cardiosphere - derived cells Macrophages Effector T - cells Proinflammatory Cytokines IFN - γ , TNF α , IL - 1 β , IL - 6, IL - 8, CXCL10, CCL2, CCL3, CCL5 Systemic Infl
Slide 4: HOPE-2 Top-Line 12-Month Data Summary
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside HOPE - 2 Top - Line 12 - month Data Summary 4 ▪ Upper Limb Function: ▪ Full PUL 2.0 – change observed of 2.4 points (p=0.05) ▪ Mid Level PUL 1.2 – change observed of 2.8 points (p=0.08) ▪ Full PUL 1.2 – change obse
Slide 5: Primary Efficacy Endpoint - Performance of the Upper Limb (Mid PUL 1.2)
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside PUL 1.2 (mid) MONTH 12/ET C A P - 1 0 0 2 P L A C E B O -15 -10 -5 0 5 M e a n C h a n g e f r o m B a s e l i n e + / - S E M p=0.0974 (t test; two-tailed) 5 Primary Efficacy Endpoint - Performance of the Upper Li
Slide 6: Performance of the Upper Limb (Full PUL 2.0)
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside -6 -5 -4 -3 -2 -1 0 PUL 2.0 (full) MONTH 12/ET M e a n C h a n g e f r o m B a s e l i n e + / - S E M CAP-1002 PLACEBO p=0.004 PUL 2.0 (full) MONTH 12/ET C A P - 1 0 0 2 P L A C E B O -8 -6 -4 -2 0 2 4 p=0.0201 (t
Capricor Therapeutics — Q1 2020 Earnings Presentation on 6ix